Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma

Core Insights - Alvotech has launched Gobivaz® (golimumab), the first marketed biosimilar to Simponi® worldwide, in Europe, with exclusive commercialization by Advanz Pharma [1][3] - The introduction of Gobivaz in the UK is supported by a National Health Service (NHS) England tender award, enhancing access to biologic treatments for immune-mediated inflammatory diseases [2] - Gobivaz's approval was backed by extensive analytical, pre-clinical, and clinical studies demonstrating its biosimilarity to the reference product, and it is manufactured at Alvotech's facility in Iceland [3] Company Overview - Alvotech is a biotechnology company focused on developing and manufacturing biosimilar medicines globally, aiming to be a leader in the biosimilar market by providing high-quality, cost-effective products [4] - The company has five biosimilars approved and marketed in various global markets, including those for Humira®, Stelara®, Simponi®, Eylea®, and Prolia®/Xgeva®, with a pipeline of nine additional biosimilar candidates targeting various diseases [4] - Alvotech has established strategic commercial partnerships to enhance its global reach and leverage local expertise across markets including the US, Europe, Japan, China, and parts of South America, Africa, and the Middle East [4]